Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2021 | Combating loss of BCMA

Mehmet Samur • 6 May 2021
IMS 2021
Multiple Myeloma Antibodies CAR-T

Loss of B-cell maturation antigen (BCMA) is an increasingly frequent challenge with the growing use of anti-BCMA therapies. In this video, Mehmet Samur, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses how we may be able to combat loss of BCMA. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.

More from Mehmet Samur

1:36
Improving the identification of patients with high-risk multiple myeloma
Mehmet Samur • 10 Dec 2022
1:34
Inherited predispositions to multiple myeloma
Mehmet Samur • 10 Dec 2022
2:37
Genomic factors impacting survival in patients with myeloma without known cytogenetic risk features
Mehmet Samur • 10 Dec 2022
3:00
Processes leading to the development of hyperdiploidy in multiple myeloma
Mehmet Samur • 10 Dec 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals